Compare · CLBS vs CO
CLBS vs CO
Side-by-side comparison of Caladrius Biosciences Inc. (CLBS) and Global Cord Blood Corporation (CO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CLBS and CO operate in Managed Health Care (Health Care), so they compete in similar markets.
- CO is the larger of the two at $476.5M, about 10.9x CLBS ($43.6M).
- Company
- Caladrius Biosciences Inc.
- Global Cord Blood Corporation
- Price
- $6.45+1176.72%
- $3.01+34.98%
- Market cap
- $43.6M
- $476.5M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Managed Health Care
- Managed Health Care
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 0
- 0
- Recent ratings
- 0
- 0
Caladrius Biosciences Inc.
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; OLOGO, a regenerative medicine advanced therapy for treating no-option refractory disabling angina; CLBS16 that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Global Cord Blood Corporation
Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. As of March 31, 2021, it operated three cord blood banks in the Beijing municipality; one in the Guangdong province; and one in the Zhejiang province. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018. Global Cord Blood Corporation is based in Central, Hong Kong.
Latest CLBS
- SEC Form 4: Mazzo David J covered exercise/tax liability with 397 shares, decreasing direct ownership by 0.41% to 96,543 units
- SEC Form 4: Mazzo David J covered exercise/tax liability with 1,030 shares, decreasing direct ownership by 1% to 96,940 units
- SEC Form 4: Ruoslahti Erkki was granted 20,000 shares
- SEC Form 4: Klosk Steven M was granted 20,000 shares, increasing direct ownership by 198% to 30,090 units
- SEC Form 4: Henson Heidi was granted 20,000 shares
- SEC Form 4: Flowers Cynthia Louise was granted 20,000 shares, increasing direct ownership by 206% to 29,721 units
- SEC Form 4: Brown Gregory B was granted 20,000 shares, increasing direct ownership by 201% to 29,934 units
- SEC Form 4: Azab Mohammad was granted 20,000 shares, increasing direct ownership by 104% to 39,200 units
- SEC Form 4: Slack David W. was granted 24,000 shares and covered exercise/tax liability with 3,358 shares
- SEC Form 4: Mazzo David J was granted 60,000 shares and covered exercise/tax liability with 11,315 shares, increasing direct ownership by 99% to 97,970 units
Latest CO
- SEC Form SC 13G/A filed by Global Cord Blood Corporation (Amendment)
- SEC Form 6-K filed by Global Cord Blood Corporation
- SEC Form 6-K filed by Global Cord Blood Corporation
- SEC Form 6-K filed by Global Cord Blood Corporation
- SEC Form 6-K filed by Global Cord Blood Corporation
- SEC Form NT 20-F filed by Global Cord Blood Corporation
- Smile, Please: In-N-Out Bans Employees From Wearing Masks In Texas And Four Other States
- SEC Form 25-NSE filed by Global Cord Blood Corporation
- SEC Form 6-K filed by Global Cord Blood Corporation
- Global Cord Blood Corporation Announces Failure To File Interim Financials